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| INTRODUC TI ON
Non-steroidal anti-inflammatory drugs (NSAIDs) comprise a group of non-chemically related compounds with similar therapeutic effects. Some of the NSAIDs are available as over-the-counter drugs, and they are commonly used in children both for their antipyretic and for their analgesic effects. 1, 2 Moreover, NSAIDs are also prescribed in pediatric patients for their anti-inflammatory properties, especially in inflammatory diseases such as juvenile idiopathic arthritis, Kawasaki disease, and acute rheumatic fever. 3, 4 NSAIDs, as with all the other drugs, may be associated with several side effects, including drug hypersensitivity reactions (DHRs).
In general, DHRs count for nearly 15% of all adverse reactions to drugs, and appear, after each exposure to the specific molecule. 5, 6 NSAIDs are among the most frequently reported drugs associated with hypersensitivity reactions, both in the adult and in the pediatric population. [7] [8] [9] [10] Even though the rate of confirmed hypersensitivity is significantly greater in adults than that in children presenting with a history of DHR, such consideration is not correct when dealing with NSAIDs. Indeed, for these drugs, the allergy rate seems greater in children. 7 Although NSAID-induced hypersensitivity reactions have mainly been investigated in adults, 11 recent studies have aimed to explore their epidemiology in the pediatric population. The aim of the present review was to give a comprehensive overview on the epidemiologic data on NSAID hypersensitivity (NSAID-H) in children and adolescents until now, focusing on the potentially different pathophysiologic mechanisms and phenotypes with particular diagnostic approaches.
| MECHANIS M OF AC TI ON OF N SAIDS
NSAIDs include more than 30 different compounds, from 7 to 9 different chemically unrelated groups (depending on the chosen classification), including paracetamol/acetaminophen ( Table 1 ).
The pharmacologic effects of NSAIDs are related to the inhibition of cyclooxygenase enzymes, (COX-I and COX-II. COX enzymes act in the synthesis of prostanoids (prostaglandins, prostacyclin, and thromboxane A2 from arachidonic acid). 12 NSAIDs prevent the binding of the arachidonic acid to the active site of the COX enzyme and therefore block the biosynthesis of prostanoids in the arachidonic acid pathway. 13 The inhibition of the prostaglandin pathway ends up with the shunting of the arachidonic acid toward the lipoxygenase pathway resulting in increased production and release of sulfidoleukotrienes. COX-I is fundamentally expressed in many different cell types. It is a structural housekeeping constitutive enzyme that plays a regulatory role under normal conditions; for example, it physiologically protects the gastrointestinal mucosa, maintains the blood flow through the kidney, and maintains the vascular homeostasis and platelet aggregation. 14 Differently from COX-I, COX-II is an inducible enzyme in case of inflammatory conditions, and the expression and biosynthesis of COX-II are increased by cytokines, mitogens, and endotoxins during activation of macrophages and some other inflammatory cells in specific tissues such as the endothelial one. 15 Cyclo-oxygenase III, another form of COX enzymes, is a different isoform targeted by paracetamol/acetaminophen, which, at low doses, is a weak inhibitor for COX-I and COX-II. 13 COX-III is encoded by the same gene with COX-1 with differences in protein sequence after splicing mechanisms. It is found mostly in brain tissue, 16 which would be an explanation for the antipyretic effect of paracetamol/ acetaminophen, even though little is known about its exact role in human tissues. Immediate IgE-mediated hypersensitivity reactions usually appear within one hour after drug intake and are mainly characterized by urticaria, angioedema, and/or anaphylaxis. 17 The reaction appears following intake of usually single or closely related NSAIDs, but alternative non-chemically related NSAIDs are well tolerated. 18 For instance in the study by Blanca-Lopez et al after determination of aspirin (ASA) tolerance with a negative OPT, patients with an immediate-type (reaction appears <1 hour after the drug intake)
| MECHANIS MS OF N SAID HYPER S EN S ITIVIT Y
hypersensitivity reaction history to any of the propionic acid derivatives were challenged with ibuprofen and other propionics.
Cross-reactivities were defined to ibuprofen, dexketoprofen, and/ or naproxen in some of the participants, which were referred as selective IgE-mediated reactions. 20 However in a recent study, it was proven that patients with a history of immediate reaction to more than one chemically different NSAIDs may also show selective responses and cross-hypersensitivity to culprit NSAIDs since they tolerate ASA. 22 The selective but non-immediate or "delayed"-type reactions appear usually 24 hours after the initial NSAID intake, and may be characterized by maculopapular exanthema, by eczema, or by even more severe forms, including fixed drug eruptions, toxic epidermal necrolysis, or organ-related reactions. 18 Three different groups of cross-intolerant reactions are listed in the current international classification: NSAID-exacerbated respiratory disease (NERD), NSAID-exacerbated cutaneous disease (NECD), and NSAID-induced urticaria and/or angioedema (NIUA). 17, 23 These reactions are related to the predominant inhibition of COX-I and decrease in prostaglandin E 2 (PGE 2 ) synthesis. Prostaglandin E 2 normally acts as a brake on the generation of sulfido-leukotrienes (LTs: LTC 4 , LTD 4 , LTE 4 ). Therefore, the lower production of PGE 2 is associated with an excessive release of LTs, resulting in the appearance of symptoms such as urticaria, angioedema, or respiratory system-related reactions. These reactions are elucidated by intake of strong COX-I inhibitors in the majority of the cases. 24 Among CI type NSAID-H phenotypes, NERD has been the most thoroughly studied one formerly known as aspirin-exacerbated respiratory disease. 24 In patients presenting with NERD, baseline serum and bronchial and urinary LTs are higher compared to NSAID-tolerant controls and they are more sensitive to the bronchoconstrictor effects of LTE 4 even at very low levels. 25 The expression of LTC 4 synthase is also increased in these patients, and a challenge with non-selective COX-1 inhibitors leads to mast cell activation as well, contributing to the emergence of hypersensitivity symptoms. 26 well as serum IL-5 and IL-13 levels, are increased. 28 Additionally, mild baseline eicosanoid imbalance is detected in three adolescents aged 17 (2 of them) and 13 years using in vitro functional eicosanoid test. 29 Similar to the patients with NERD, patients with NECD also exhibit increased levels of baseline urinary LTE 4 levels, which further significantly increase together with the expression of the activation marker of basophils (CD203c) upon challenge with a strong COX-I inhibitor. 30, 31 However, there are some variations in eicosanoid levels when the nasal lavage of the patients with NERD and NIUA is compared upon nasal lysine-aspirin challenge. 32 Tryptase and eosinophilic cationic protein levels are higher in patients with NERD compared to the patients with NIUA, and besides the significant increase in PGD 2, LTD 4 and LTE 4 levels are found compared to baseline in only patients with NERD at the end of the lysine-aspirin challenge, whereas no significant change is found in patients with NIUA. 32 The results of this study suggest that the consequences of COX inhibition mainly take place in skin in patients with NIUA, but the role of eicosanoids in its pathogenesis is still not clear. The mentioned results are obtained from animal studies or from mainly adult populations. The pathophysiologic mechanisms implicated in NSAID-H in children still need to be better investigated and clarified.
| EPIDEMI OLOGY AND CLINIC AL MANIFE S TATIONS IN D IFFERENT PHENOT YPE S OF N SAID HYPER S EN S ITIVIT Y IN CHILDREN
The phenotypical description of NSAID-H is typically based on the signs and symptoms characterizing the reaction, the time period between the drug intake and the symptom appearance, and the existence of cross-intolerance with other chemical groups of NSAIDs together with the presence of an underlying chronic disorder. 33 According to ENDA/EAACI/GA 2 LEN recommendations, 17,34 the five aforementioned phenotypes of NSAID-H are mainly based on authors' expertise and published evidence; these studies mainly focus on the adult population ( Table 2 ). Subsequent to the publication of these recommendations, several authors focused their studies on the pediatric population, describing similar and divergent phenotypes of NSAID-H in children. [35] [36] [37] [38] [39] [40] Aspirin was the first synthetic compound introduced into medicine for its analgesic and antipyretic effects in 1899 by Dreser. 41 A short while after its first use, different types of hypersensitivity reactions to aspirin were described, and for a long time, it was used as a prototype of the other NSAIDs to define hypersensitivity reactions. The first studies on NSAID-H in children aimed to find out the rate of aspirin hypersensitivity (ASA-H) in asthmatic [42] [43] [44] [45] [46] and healthy populations regardless of a suspected drug-induced history, 47, 48 which were detected by aspirin provocation tests and highlighted a prevalence of 0%-33% and 0.32%-0.55%, respectively (Table 3) .
In more recent studies, children and adolescents with a suspected history of NSAID-induced hypersensitivity reaction were challenged with the culprit drug in order to define the prevalence of proven NSAID-H, which is assessed between 8% and 68% in different populations. 35, 36, 38, 39, [49] [50] [51] [52] As an important finding in these studies, the most commonly implicated culprit NSAIDs resulting in confirmed hypersensitivity in young children were ibuprofen, paracetamol and to a lesser extent metamizole, while diclofenac, naproxen, aspirin, and ketoprofen were more common in adolescents. 35 Cutaneous symptoms such as urticaria and angioedema are the most frequent reactions appearing during NSAID-induced hypersensitivity reactions in children. 35, 36 In adults, the most frequent clinical manifestation is CI type urticaria and/or angioedema and to a lesser extent respiratory involvement, 53 whereas in children, there are contradictory results. 36, 38, 50 In one of the largest published series, there were slightly more cross-intolerant patients than selective responders, 35 but this was not the case in smaller studies. 50 One important clinical feature is isolated facial angioedema 57 especially localized on lips or eyelids, which seems to be more frequent in crossintolerants. 35, 58 In a study from Singapore, including atopic children, facial angioedema developed in all CI patients during OPTs, 58 and in another one, including children younger than 6 years, it was the most common clinical manifestation, with a frequency of 83%. 57 The incidence of NSAID-induced facial angioedema was reported to increase with age in an atopic group of children and adolescents, being reported in less than 5% of infants and toddlers, but in up to 20% of adolescents and young adults. 59 In a study analyzing the causative agents for a history of isolated angioedema, drug provocation tests were positive merely for NSAIDs although hypersensitivity to different antibiotics was also initially suspected based on the reported clinical history. 60 In patients with chronic urticaria, OPTs with aspirin resulted in positive reactions as isolated lip or periorbital angioedema establishing a rate of NECD as 24% in this group of children and adolescents. 37 Localized periorbital angioedema induced by NSAIDs was also described in adult patients with chronic urticaria 61 or allergic rhinitis, conjunctivitis, or asthma or in patients without any underlying disease 62 but mostly in young adults. The underlying mechanism inducing such a distinctive phenomenon and its association with atopy and age still needs to be clarified.
NSAID-induced delayed reactions (SNIDRs) are very rare both in adults and in children 6, 36, 40, 50, 54 ( reactions also exist in this group, but the exact prevalence in children is not known. Although rare, it is important to note that NSAID use can also be a risk factor for severe cutaneous hypersensitivity reactions 64 and can result in significant morbidity and mortality in children. 63, 65 NSAID-exacerbated respiratory disease (NERD) formerly known as aspirin-exacerbated respiratory disease 34 68 Nasal polyposis is a rare condition before adolescence (with the exception of children suffering from cystic fibrosis) 69 and may exhibit different clinical features and symptomatic progression. 29, 42, 70 In a study, from 1973, evaluating medical records from 1298 asthmatic children, the prevalence of aspirin hypersensitivity (ASA-H) was 1.9%. 71 Non-steroidal anti-inflammatory drug hypersensitivity in asthmatic children and adolescents (mean age:
years) was firstly confirmed with placebo-controlled OPTs by
Rachelefsky et al 42 In this study, aspirin-induced bronchospasm was defined as at least a 30% decrease in FEV 1 and MEF 25-75 levels compared to baseline and to placebo: 28% of the 50 included asthmatic patients were diagnosed as aspirin-intolerant. Females were more frequent in NSAID-H group, they had more episodes of sinusitis, and their asthma showed an earlier onset compared to NSAID-tolerant children, even though neither nasal eosinophilia nor steroid dependency differed in the two groups. 42 Another study confirmed ASA-H through OPT in 12.5% of children with asthma. 72 Estrada-Rodriguez et al compared 16 aspirin-intolerant asthmatics aged between 2 and 14 years with aspirin-tolerant asthmatic children and reported that, contrary to the results published on adults, females are not predisposed to aspirin hypersensitivity in childhood, and, interestingly, they even diagnosed an ASA-H in a 1-year-old patient. 70 More recent publications on childhood NERD include single case reports or case series. 28, 29, 73, 74 In a series of 10 CI NSAID-induced hypersensitive patients with a mean age of 14.9 ± 1.5 years, the clinical features of this phenotype are thoroughly described. 73 In this study, NERD was confirmed with at least two chemically unrelated positive NSAID provocation tests and patients were followed up for at least 2 years. Allf but one patient initially exhibited asthma symptoms before chronic upper respiratory airway disease related symptoms, and only two patients had a polypectomy history. Chronic rhinosinusitis with nasal polyposis was found in only one patient at the time of diagnosis. The majority of patients had mild persistent asthma, not requiring systemic corticosteroid courses during the follow-up; half of the patients were also diagnosed as suffering from allergic rhinitis.
Also, these patients presented cutaneous manifestations associated with respiratory symptoms, during provocation tests, diverging from the clinical features of NERD in adults. 68, 73 On the other hand in the most recent study, 976 children and adolescents with asthma were compared with 2000 age-and sex-matched healthy controls, and NERD and SNIUAA were found in 3 (0.03%) and 6 (0.06%) children with asthma, whereas none was detected in the control group. 75 In contrast to the previous studies, 42, 72 OPT with ASA was not performed for all patients with asthma; instead, patients and healthy controls were initially challenged with the culprit drug in case of a suspected reaction with any of the NSAIDs in the history, and ASA challenge was performed to assess cross-intolerance and selective responsivity if the initial OPT was positive. 75 Besides these studies, other authors suggested that NSAID-H in children might not perfectly fit the phenotypes proposed by the current classification 36, 40 with the main discrepancy being the concurrent appearance of both cutaneous and respiratory symptoms in CI patients. This variant has been described as "blended reactions"
or "mixed clinical picture of urticaria/angioedema and respiratory symptoms (cough, breathlessness, hoarseness, wheezing, rhinorrhea)". 52 In the largest study (n = 635) on phenotypical characterization of NSAID-H in childhood by Cousin et al, 40 .2% of children with a confirmed NSAID-H could not be classified according to EAACI/ ENDA recommendations. 17 The main issue raised by the authors was that in CI pediatric patients, clinical manifestations did not correlate with underlying diseases; particularly, no patient could strictly correspond to the NERD group. The authors proposed a new possible classification gathering the 3 cross-intolerant NSAID-H types into one sole group, while they did not modify the two immunologic-mediated groups. 40 On the other hand, blended reactions may be seen in children and adolescents with chronic urticaria or asthma as well as in patients without any underlying chronic disease. 36 Finally, in a recent study involving a high number of adults with a confirmed NSAID-H, blended reactions were defined in only five patients comprising 1.6% of the participants. 54 Further studies are therefore needed to better define and classify NSAID-H composing different age-groups.
| NSAID -INDUCED ANAPHYL A XIS IN CHILDREN
Data on drug-induced anaphylaxis (DIA) in pediatrics are limited and mostly published as part of adult studies on drug reactions or on anaphylactic reactions. [76] [77] [78] [79] [80] In children and adolescents with NSAID-H, anaphylactic reactions may occur, resulting in life-threatening and fatal events. 80 In a national Polish survey on DIA, almost 50% of the culprit drugs were NSAIDs and 8.3% of the participants who reported a history DIA were younger than 18 years of age at the time of the reaction. Non-steroidal anti-inflammatory drugs were also responsible for most recurrent anaphylaxis, mainly related to crossintolerant COX-I inhibitors. 76 Another survey run in Latin America showed that NSAIDs were the most frequent cause of anaphylaxis, especially in adolescents. 79 In a multicenter study, NSAIDs were proven to be the most frequent trigger of drug-induced anaphylaxis in a group of patients aged between 2 and 70 years, 77 whereas in another recent paper involving pediatric patients only, they represented the second most frequently drug-inducing anaphylactic reactions. 81 In a smaller Brazilian cohort with a total of 26 anaphylactic reactions due to drugs, NSAIDs were the responsible class in 62% of cases. 82 
| RIS K FAC TOR S FOR N SAID -H IN CHILDHOOD
The most important clinical determinant of NSAID-H is the presence of atopy and atopic diseases both in adults and in children, 35, 39, 40, 53, 83, 84 which might be related to some ethnic, genetic, and environmental factors. In adults depending on the population studied, atopy was defined as an associated factor for either selective 84 or cross-intolerant type of NSAID-H. 85 Chronic urticaria, sensitization to inhalant allergens, and allergic rhinoconjunctivitis are considered as independent risk factors for NSAID-H in childhood. 40 Sanchez-Borges et al reported that atopic disease was found in 93%
of children and adolescents with a confirmed NSAID-H, and most of them suffered from allergic rhinitis or allergic rhinitis and asthma. 52 Zambonino et al reported that mainly food allergy, but also inhalant allergen sensitization, was significantly more frequent in CI children and adolescents compared to SRs and healthy controls, and sensitization to, particularly, house dust mites, Olea europaea, and
Alternaria was the most frequently associated inhalant allergens. 35 Nevertheless, these findings were not confirmed in other studies. 36, 38, 39 The clinical manifestations occurring during the index reaction may also be predictive of the result of a provocation test.
Indeed, an immediate reaction, characterized by respiratory symptoms, associated with a reported history of reactions to multiple unrelated NSAIDs increases the risk of an actual NSAID-H in childhood. 36, 38 Gender was not a predictive factor in childhood; on the other hand, gender and age were significant prognostic factors in adulthood, being women decreased the risk in multivariate logistic regression analysis and subjects older than 40 years had a lower risk of actual NSAID-H. 86 However in another study involving patients older than 18 years, gender and atopy were not risk factors while having immediate reaction and existence of more than one reaction to a NSAID in the history increased the likelihood of confirmed hypersensitivity to NSAIDs. 87 
| PR AC TI C AL APPROACH TO D IAG NOS E N SAID -H IN CHILDHOOD
The investigation of suspected NSAID-H begins with a thorough evaluation of the reported clinical history. In case of a suspected immediate IgE-mediated hypersensitivity reaction such as urticaria, angioedema, respiratory symptoms, or anaphylaxis, it is possible to perform skin prick and intradermal tests for some NSAIDs. The most commonly described skin tests in children were performed with metamizole, phenylbutazone, and paracetamol. 10, 36, 39, 50 weight of the patients. Where an OPT is positive, and depending on the severity of past reactions, it may be necessary to perform additional challenges on a separate occasion with a strong COX-I inhibitor such as ibuprofen to assess for cross-intolerance ( Figure 1) . 35, 36, 38, 50 According to the published studies, for the diagnosis of NSAID-H one possible approach is to initially identify patients who report a reaction to either a single NSAID or a multiple NSAIDs according to the history and perform the extra OPT with aspirin only to those belonging to the latter group. 39 In this condition, the physician relies strongly on the history, but it is also important to consider that the reported history in children is not always reliable. In fact, children with a history of single NSAID-induced hypersensitivity reaction may actually be cross-intolerant, while children who experienced a reaction to multiple NSAIDs may be classified as selective responder at the end of the allergy workup. 36 Therefore, performing an extra OPT with a non-selective COX inhibitor such as ibuprofen in children with a confirmed NSAID-H may be necessary to define the actual cross-intolerance and to search for a safe alternative drug. The initial approach may differ in some particular situations and must be decided individually. In some clinical conditions, especially in the case of severe reactions, performing provocation test with the culprit drug is not essential. As an example, as per the NICE recommendations, if the index reaction is severe, and if there is an ongoing immediate clinical requirement for a NSAID, the initial supervised trial of a COX-II inhibitor has been previously recommended.
91
Another possible approach is performing an initial OPT with aspirin to the patients with an DHR to any of the NSAIDs and performing the provocation test with the culprit drug in case of a negative aspirin test. In a recent study, an initial OPT with aspirin was performed for all children and adolescents with a history of suspected NSAID-H reaction, followed by an OPT with the culprit drug, whenever the previous test was negative. By doing that, patients with ASA-H were only tested once 92 and directly defined as cross-intolerant. 93 While the authors highlight that this approach may be considered as safe and less time-consuming, nevertheless, the use of aspirin might be a matter of concern in children due to different clinical conditions to the amount of paracetamol/acetaminophen used for OPT. 95 In fact, in a case series of 41 CI patients aged between 9 and 14 years, OPTs to etoricoxib and high-dose paracetamol/acetaminophen (15 mg/kg) were negative for all the patients and only two reacted to meloxicam with a mild type cutaneous reaction. 94 However, high cumulative doses of paracetamol/acetaminophen revealed hypersensitivity reactions in 2 of 7 CI children. 95 These reactions may be due to the fact that, at high doses, paracetamol/acetaminophen may show anti-COX-I properties.
The age of the patient might also be a limitation, since nimesulide and meloxicam are only approved for adolescents older than 12 and 15 years respectively. Highly selective COX-II inhibitors (coxibs), such as etoricoxib, might also be an option for older children, 52, 94 but there had been some F I G U R E 1 Possible diagnostic algorithm for children and adolescents with a suspected hypersensitivity reaction to a non-steroidal anti-inflammatory drug. CI, cross-intolerant, COX-1, cyclooxygenase I, NSAID-H, non-steroidal antiinflammatory drug hypersensitivity, OPT, oral provocation test F I G U R E 2 Action of non-steroidal anti-inflammatory drugs on cyclooxygenase enzymes concern in relation to the increased risk of serious cardiovascular events, and several coxibs were withdrawn from the market in many countries. 96 
| CON CLUS IONS
The prevalence of hypersensitivity reactions to NSAIDs seems to be similar in children and adults, but differences are noted in the clini- 
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